
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. reported a solid third-quarter performance with a top-line revenue of $191.8 million, reflecting a 10% quarter-over-quarter and 5% year-over-year increase, surpassing market expectations. The company's Baqsimi and Primatene Mist products exhibited strong sales growth, with Baqsimi experiencing a notable 20% quarter-over-quarter increase in prescriptions, bolstered by strategic collaborations and seasonal demand. Looking ahead, Amphastar anticipates a return to double-digit growth by 2026, along with positive expectations for new product approvals and launches in the near term, indicating a favorable outlook for the company’s financial performance.
Bears say
Amphastar Pharmaceuticals Inc. faces significant revenue pressures as initial sales for its iron sucrose product have come in at only $2.4 million for the second half of Q3 2025, with revised quarterly expectations now estimated at around $5 million, a substantial drop from previous projections of $60 million due to rising competition and supply chain issues. Additionally, the company anticipates further declines in glucagon sales, which are expected to fall below $70 million by 2026, as competition intensifies in this segment and new market entrants exert downward pressure on pricing and demand. Overall, the outlook for Amphastar's top-line growth has been tempered, with forecasts now suggesting only high-single to low-double-digit growth in 2026, against earlier expectations of robust double-digit increases, further compounding concerns about the company's financial trajectory.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares